Eli Lilly's new oral GLP-1 drug, orforglipron, shows similar effectiveness to popular injectable medications like Ozempic for weight loss and blood sugar control in Type 2 diabetes patients. The company plans to seek FDA approval for the pill, which could revolutionize treatment options, pending its pricing strategy and safety data release.